Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be a
(Financial Post, 2025-12-12T13:33:28Z)